Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Papp

Showing results (301-310 of 461) with videos related to

Pageof 47
Sort By:
Human Molecular Genetics|June 1, 1993
Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophyA V Winnard, C J Klein, D D Coovert, et al.
Dermatology and Therapy|July 8, 2021
The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area ScoreKim A Papp, Mark G Lebwohl, Leon H Kircik, et al.
Blockchain in Healthcare Today|February 13, 2023
Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial PilotBaldwin C Mak, Bryan T Addeman, Jia Chen, et al.
Rheumatology and Therapy|August 5, 2022
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized TrialPhilip J Mease, Herbert Kellner, Akimichi Morita, et al.
The American Journal of Psychiatry|February 1, 1993
Diagnostic and substance specificity of carbon-dioxide-induced panicL A Papp, D F Klein, J Martinez, et al.
Journal of the American Academy of Dermatology|February 5, 2005
Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccinationKim A Papp, Kristine Breuer, Michael Meurer, et al.
The Journal of Investigative Dermatology|October 21, 2011
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasisKenneth B Gordon, Richard G Langley, Alice B Gottlieb, et al.
The British Journal of Dermatology|June 14, 2005
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionK A Papp, S Tyring, M Lahfa, et al.
Dermatology and Therapy|April 25, 2025
Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical TherapiesMelinda J Gooderham, H Chih-Ho Hong, Charles Lynde, et al.
Burns : Journal of the International Society for Burn Injuries|September 26, 2021
Choosing wisely in burn careA D Rogers, A Amaral, R Cartotto, et al.
Pageof 47

Showing results (301-310 of 461) with videos related to

Sort By:
Pageof 47
Human Molecular Genetics|June 1, 1993
Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophyA V Winnard, C J Klein, D D Coovert, et al.
Dermatology and Therapy|July 8, 2021
The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area ScoreKim A Papp, Mark G Lebwohl, Leon H Kircik, et al.
Blockchain in Healthcare Today|February 13, 2023
Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial PilotBaldwin C Mak, Bryan T Addeman, Jia Chen, et al.
Rheumatology and Therapy|August 5, 2022
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized TrialPhilip J Mease, Herbert Kellner, Akimichi Morita, et al.
The American Journal of Psychiatry|February 1, 1993
Diagnostic and substance specificity of carbon-dioxide-induced panicL A Papp, D F Klein, J Martinez, et al.
Journal of the American Academy of Dermatology|February 5, 2005
Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccinationKim A Papp, Kristine Breuer, Michael Meurer, et al.
The Journal of Investigative Dermatology|October 21, 2011
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasisKenneth B Gordon, Richard G Langley, Alice B Gottlieb, et al.
The British Journal of Dermatology|June 14, 2005
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionK A Papp, S Tyring, M Lahfa, et al.
Dermatology and Therapy|April 25, 2025
Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical TherapiesMelinda J Gooderham, H Chih-Ho Hong, Charles Lynde, et al.
Burns : Journal of the International Society for Burn Injuries|September 26, 2021
Choosing wisely in burn careA D Rogers, A Amaral, R Cartotto, et al.
Pageof 47